Christopher Marai
Stock Analyst at Nomura
(2.41)
# 2,490
Out of 5,116 analysts
33
Total ratings
51.61%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Marai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $360 → $960 | $8.27 | +11,508.22% | 2 | Jun 4, 2020 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $29 → $33 | $81.80 | -59.66% | 2 | May 11, 2020 | |
| SLDB Solid Biosciences | Maintains: Buy | $150 → $90 | $6.46 | +1,293.19% | 5 | May 8, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | $74 | $338.06 | -78.11% | 4 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $37 → $16 | $3.90 | +310.26% | 2 | Mar 30, 2020 | |
| BIIB Biogen | Maintains: Buy | $320 → $392 | $179.89 | +117.91% | 7 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | $34 | $1.54 | +2,107.79% | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $205 → $230 | $20.34 | +1,030.78% | 3 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $22 → $12 | $20.31 | -40.92% | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | $87 → $19 | $8.81 | +115.66% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $43 | $3.79 | +1,034.56% | 2 | Sep 6, 2017 |
Corbus Pharmaceuticals Holdings
Jun 4, 2020
Maintains: Buy
Price Target: $360 → $960
Current: $8.27
Upside: +11,508.22%
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: $29 → $33
Current: $81.80
Upside: -59.66%
Solid Biosciences
May 8, 2020
Maintains: Buy
Price Target: $150 → $90
Current: $6.46
Upside: +1,293.19%
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: $74
Current: $338.06
Upside: -78.11%
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: $37 → $16
Current: $3.90
Upside: +310.26%
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: $320 → $392
Current: $179.89
Upside: +117.91%
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: $34
Current: $1.54
Upside: +2,107.79%
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: $205 → $230
Current: $20.34
Upside: +1,030.78%
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $22 → $12
Current: $20.31
Upside: -40.92%
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: $87 → $19
Current: $8.81
Upside: +115.66%
Sep 6, 2017
Maintains: Buy
Price Target: $49 → $43
Current: $3.79
Upside: +1,034.56%